CGRP Monoclonal Antibody Therapy for Chronic Migraine in a Patient Refractory to Botox and Triple Oral Prophylaxis

Condition

The patient had a long-standing history of episodic migraine that gradually transformed into chronic migraine over several years, eventually reaching 22 headache days a month by the time she was referred to Dr. Guruprasad Hosurkar, a neurologist in Bangalore with a dedicated headache and migraine practice. Attacks were throbbing, one-sided more often than not, and accompanied by nausea, light and sound sensitivity, and scalp tenderness that made even brushing her hair painful on bad days.

She had already completed adequate, well-tolerated trials of three separate oral preventive medication classes: topiramate, propranolol, and amitriptyline, each given for at least eight weeks at an effective dose, without meaningful reduction in headache frequency. Three cycles of OnabotulinumtoxinA using the standard PREEMPT injection protocol, given twelve weeks apart, produced only a marginal, short-lived improvement. Frequent use of triptans and NSAIDs to manage acute attacks had, over time, added a component of medication-overuse headache, further complicating the clinical picture.

Emotional and Psychological Impact

By the time of referral, the patient had used the majority of her paid leave on headache days and had begun avoiding client-facing meetings she could not reliably guarantee attending. She described a persistent low-grade anxiety about the next attack, and a sense that she had already tried everything reasonable without result. The initial consultation focused on validating that her migraine was genuinely treatment-refractory by standard definitions, not a sign that nothing further could be done, and on introducing CGRP monoclonal antibody therapy as a distinct mechanism from everything she had tried so far.

Why This Approach Was Chosen

Her chronic migraine met accepted criteria for treatment-refractory disease: inadequate response to three appropriately dosed oral preventive classes and to OnabotulinumtoxinA. This is the specific population in which CGRP monoclonal antibody therapy has the strongest evidence base, since it targets the calcitonin gene-related peptide pathway through a mechanism distinct from both her prior oral preventives and Botox. Addressing the medication-overuse component in parallel was essential, since overuse of acute medication can blunt the benefit of any preventive therapy if left unmanaged.

“When a patient has genuinely failed three well-chosen oral preventives and a full course of Botox, that is not the end of the road, it usually means we need a therapy that works through a different pathway altogether. CGRP monoclonal antibodies target the mechanism directly, and in appropriately refractory patients the response can be dramatic and rapid.” — Dr. Guruprasad Hosurkar. Full details on our Headache and Migraine Treatment blog.

Treatment Facts